Huntington’s Disease Treatment Industry

The global Huntington’s disease treatment market size is projected to reach USD 1,871.2 million by the year 2030, registering a compound annual growth rate (CAGR) of 23.8% from 2025 to 2030, as reported by Grand View Research, Inc. This anticipated growth is primarily driven by substantial investments in research and development aimed at the introduction of new therapies, collaborative research initiatives, and the considerable burden of Huntington’s disease (HD) in Western countries. Huntington's disease is a rare, inherited neurodegenerative disorder that affects multiple generations within families. The condition typically manifests in individuals between the ages of 30 and 50, significantly impairing their ability to maintain employment, provide care for their families, and eventually perform routine daily activities.

The prevalence of Huntington’s disease varies more than ten-fold across different geographical regions. This variation can be attributed to differences in how cases are identified and diagnosed, including disparities in case ascertainment practices and diagnostic criteria. Consequently, the number of individuals with genetic expansions associated with the disease in the general population may be higher than previously estimated. Epidemiological studies indicate that the prevalence of Huntington’s disease remains consistently lower in Asian populations, whereas it is notably higher in regions such as Europe, North America, and Australia.

Key pharmaceutical companies, including Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are currently concentrating their efforts on the research and development of symptomatic treatments for Huntington’s disease. Azevan Pharmaceuticals is specifically working on the development of SRX246, an experimental therapeutic agent designed to address the neuropsychiatric symptoms commonly seen in patients with HD. SRX246 operates by targeting and blocking the vasopressin 1a (V1a) receptor in the brain. The V1a receptor is the primary vasopressin receptor within the nervous system. By inhibiting this receptor, SRX246 prevents vasopressin from binding, which in turn helps reduce symptoms such as irritability and aggression that are frequently observed in individuals affected by Huntington’s disease.

Despite ongoing advancements, currently approved medications for Huntington’s disease offer only symptomatic relief and palliative care, without addressing the underlying causes of the condition. While these treatments may alleviate symptom severity, they are often linked with undesirable side effects such as excessive drowsiness, balance and gait disturbances, difficulty swallowing (dysphagia), and emotional detachment (apathy). These side effects can significantly impact the overall quality of life for patients. Since there is no known cure for Huntington’s disease, it becomes crucial to assess how the illness affects Health-related Quality of Life (HRQOL). Patients in the early to middle stages of the disease require integrated, multidisciplinary healthcare services, which typically involve cognitive function evaluations, psychological counseling, and regular medical monitoring.

The development of drugs specifically for Huntington’s disease has encountered substantial challenges, as numerous therapeutic candidates have failed to demonstrate sufficient efficacy or have been linked with considerable toxicity. For example, in September 2020, Vaccinex Inc. announced the results of a phase II clinical trial for its investigational drug Pepinemab. The trial, which targeted patients with early manifest and prodromal HD, did not meet its two pre-specified co-primary endpoints. These endpoints included a pair of cognitive assessments from the Huntington’s Disease Cognitive Assessment Battery and the Clinical Global Impression of Change (CGIC). In the SIGNAL study, neither of these endpoints reached statistical significance in the population with early-stage symptoms, highlighting the ongoing difficulty in finding effective disease-modifying treatments for Huntington’s disease.

Curious about the Huntington’s Disease Treatment Market, Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

Huntington’s Disease Treatment Market Segments Highlights:

  • The symptomatic treatment segment accounted for the largest revenue share in 2024 owing to the product availability and patent protection. Disease-modifying therapies is anticipated to be the fastest-growing segment over the forecast years due to the entry of SAGE-718, and Cellavita-HD
  • Companies are now focusing on the development of treatments that can be injected directly into the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein
  • Drugs with novel targets in early-phase development include Cellavita and Azidus Brazil’s Cellavita HD (stem cell therapy), Sangamo Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure’s AMT-130 (gene therapy)
  • North America held the highest revenue share in 2024 and is expected to dominate the market over the forecast period due to better reimbursement facilities and the high burden of HD in the U.S. and Canada

Huntington’s Disease Treatment Market Report Segmentation

Grand View Research has segmented the global Huntington’s disease treatment market report based on treatment, distribution channel, and region:

Huntington’s Disease Treatment Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Symptomatic Treatment
  • Disease-modifying Therapies

Huntington’s Disease Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Huntington’s Disease Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Kuwait
    • UAE

Key Huntington’s Disease Treatment Company Insights

  • Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Companies Inc.
  • Hetero
  • Lupin
  • Hikma Pharmaceuticals PLC
  • Reddy’s Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • uniQure NV.
  • Latus Bio

Order a free sample PDF of the Huntington’s Disease Treatment Market Intelligence Study, published by Grand View Research.